WO 2005/077082 PCT/US2005/004281

## WHAT IS CLAIMED IS:

5

10

15

20

1. An antibody that specifically binds to a Cav3 isoform or its  $\delta 25$  splicing variants thereof.

- 2. The antibody of Claim 1, wherein the Cav3 isoform is a Cav3.2 isoform.
  - 3. The antibody of Claim 1, wherein the antibody is a humanized antibody.
- A pharmaceutical composition comprising an antibody of Claim 1 or Claim 3 and a pharmaceutically acceptable carrier.
  - 5. A method for diagnosing cancer comprising detecting the presence of a Cav3 isoform protein and/or its  $\delta$ 25B splice variant in a tissue sample from a patient.
  - 6. A method for treating cancer comprising detecting the presence of a Cav3 isoform protein and/or its δ25B splice variant in a patient according to Claim 5 and administering to the patient a therapeutically effective amount of an antibody against the Cav3 isoform and/or its δ25B.
  - 7. A method for treating or control cancer comprising administering to a patient in need thereof a therapeutically effective amount T type calcium channel selective inhibitor.
  - 8. The method of Claim 7, wherein the T type calcium channel selective inhibitor is a tetrahydronaphthalene derivative of the formula

25

wherein  $\mathbb{R}^1$  is a halogen,  $\mathbb{R}^2$  is a lower-alkoxy-lower-alkyl-carbonyloxy, X is a  $\mathbb{C}_2$ - $\mathbb{C}_8$ -alkylene, and A is a benzimidazolyl

WO 2005/077082 PCT/US2005/004281

optionally substituted at the N atom with 1 to 12 C atoms in the form of their free bases, their hydrates, or their pharmaceutically usable salts for the treatment, control, and prevention of cancer. The method of Claim 7, wherein the T type calcium channel selective 9. inhibitor is a mibefradil of the formula (1S,2S)-(2{[3-(2-5 benzimidazolyl) propyl] methylamino} ethyl)-6-fluoro-1,2,3,4tetrahydro-1-isopropyl-2-naphthylmethoxyacetate dihydrochloride. 10. A method of inhibiting cancer cell proliferation comprising administering to a patient in need thereof a therapeutically effective 10 amount of mibefradil. A method for inhibiting calcium entry into electrically non-excitable 11. cells comprising administering a T type calcium channel selective inhibitor. The method of Claim 11, wherein the electrically non-excitable cells 12. 15 are selected from the group consisting of lymphocytes, epithelial cells, connective tissue cells, secretory cells, Jurkat T-cells, MDA-468 cells and PC-3 cells. 13. A method of treating autoimmune diseases comprising administering to a patient in need thereof a therapeutically effective amount of T type 20 calcium channel selective inhibitor. 14. A method for preventing graft rejections comprising administering to a patient in need thereof a therapeutically effective amount of T type calcium channel selective inhibitor. 15. A method for preventing apoptosis comprising administering to a patient in need thereof a therapeutically effective amount of T type 25 calcium channel selective inhibitor.